Lv1
40 积分 2022-09-14 加入
Setting and Titrating Positive End-Expiratory Pressure
9小时前
待确认
High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse
1年前
已完结
Have we been qualifying measurable residual disease correctly?
1年前
已完结
Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study
1年前
已完结
Evaluating the treatment of cutaneous adverse events and adherence to National Comprehensive Cancer Network guidelines in patients receiving immune checkpoint inhibitors
1年前
已完结
SOHO State of the Art Updates and Next Questions: Mini-Hyper-CVD Combinations for Older Adults: Results of Recent Trials and a Glimpse into the Future
1年前
已完结
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
1年前
已完结
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial
1年前
已完结
CAR T-Cell Therapy in the Older Person: Indications and Risks
1年前
已完结
皖公网安备34019202002308
